PT 00114

Drug Profile

PT 00114

Alternative Names: PT 00114

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protagenic Therapeutics
  • Developer Charles River Laboratories; Protagenic Therapeutics
  • Class Antidepressants; Peptides
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Depressive disorders; Impulse control disorders; Neurodegenerative disorders; Opioid abuse

Most Recent Events

  • 05 Oct 2017 Pharmacodynamics data from a preclinical trial in Anxiety disorders and Depressive disorders released by Protagenic Therapeutics
  • 28 Sep 2017 Preclinical trials in Anxiety disorders in Finland (SC), before September 2017
  • 28 Sep 2017 Preclinical trials in Depressive disorders in Finland (SC), before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top